BioHedge Weekly
13D/13G filings from 17 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform with clinical trials, SEC filings, and hedge fund positioning, linked by company.
Get next week's BioHedge Weekly by email
One email per week. We follow up on coverage that's relevant to you.
Weekly Filing Volume
Filings This Week
| Fund / Company | Ownership & Type |
|---|---|
Deerfield Management BIOCRYST PHARMACEUTICALS INC (BCRX) | 6.8% +1.0 13G/A [SEC] |
Deerfield Management Nuvalent, Inc. (NUVL) | 24.2% -3.4 13G/A [SEC] |
OrbiMed MBX Biosciences (MBX) | 7.7% -1.3 13D/A [SEC] |
Deerfield Management BiomX Inc. (PHGE) | 10.0% 13D/A [SEC] |
Baker Brothers Advisors INCYTE CORP (INCY) | 15.7% 13D/A [SEC] |
Third Rock Ventures Tango Therapeutics, Inc. (TNGX) | 4.7% -1.1 13D/A [SEC] |
Perceptive Advisors Astria Therapeutics, Inc. (ATXS) | 0.0% 13D/A [SEC] |
RA Capital Management ALX Oncology Inc. (ALXO) | 9.9% New 13G [SEC] |
New Positions
Funds disclosing more than 5% ownership in a company for the first time.
| Fund / Company | Ownership & Type |
|---|---|
RA Capital Management ALX Oncology Inc. (ALXO) | 9.9% SC 13G [SEC] |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses more than 5% ownership in a company for the first time.
We track 17 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.